Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-22-088032
Filing Date
2022-08-09
Accepted
2022-08-09 17:20:21
Documents
2
Group Members
AVISTA HEALTHCARE PARTNERS GP, LTD.AVISTA HEALTHCARE PARTNERS, L.P.ORBIT CO-INVEST III LLCORBIT CO-INVEST III LLC

Document Format Files

Seq Description Document Type Size
1 SC 13D/A tm2222989d1_sc13da.htm SC 13D/A 61106
2 EXHIBIT 1 tm2222989d1_ex1.htm EX-1 134922
  Complete submission text file 0001104659-22-088032.txt   197861
Mailing Address C/O AVISTA CAPITAL PARTNERS, 65 EAST 55T NEW YORK NY 10022
Business Address C/O AVISTA CAPITAL PARTNERS, 65 EAST 55T NEW YORK NY 10022 2125936900
Avista Capital Partners III GP, L.P. (Filed by) CIK: 0001705722 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807
Business Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 9088091300
RVL Pharmaceuticals plc (Subject) CIK: 0001739426 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90830 | Film No.: 221149503
SIC: 2834 Pharmaceutical Preparations